International partnership to advance the development of a new vaccine against Shigella and ETEC
Horizon2020 award to consortium will support the testing of an innovative live attenuated vaccine in phase I clinical trials in Europe and Bangladesh.
Under coordination by EVI, the SHIGETECVAX consortium, made up of partners including EVI, Eveliqure, icddr,b, University of Gothenburg, and PATH, will be advancing a radically new approach for a vaccine against Shigella and ETEC, developed by Eveliqure Biotechnologies.
To read the full EVI news release, please click this link:
To read the full EVQ news release, please click this link: